WO2023151172A1 - Vaccin à vecteur adénoviral pour la prévention contre une souche omicron du sars-cov-2 - Google Patents
Vaccin à vecteur adénoviral pour la prévention contre une souche omicron du sars-cov-2 Download PDFInfo
- Publication number
- WO2023151172A1 WO2023151172A1 PCT/CN2022/085800 CN2022085800W WO2023151172A1 WO 2023151172 A1 WO2023151172 A1 WO 2023151172A1 CN 2022085800 W CN2022085800 W CN 2022085800W WO 2023151172 A1 WO2023151172 A1 WO 2023151172A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector
- vaccine
- cov
- omicron
- nucleic acid
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
Abstract
La présente invention concerne un vaccin à vecteur adénoviral pour la prévention contre une souche SARS-CoV-2 Omicron. Selon la présente invention, une nouvelle séquence du gène S est obtenue par optimisation en utilisant le biais d'usage des codons. La nouvelle séquence du gène S peut être exprimée efficacement dans les cellules humaines. Un organisme immunisé peut exprimer un antigène S de manière efficace et générer des anticorps neutralisants ciblant la souche SARS-CoV-2 Omicron, ce qui protège efficacement l'organisme contre l'infection par la souche Omicron.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210120315.4 | 2022-02-09 | ||
CN202210120315.4A CN114150005B (zh) | 2022-02-09 | 2022-02-09 | 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023151172A1 true WO2023151172A1 (fr) | 2023-08-17 |
Family
ID=80450043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/085800 WO2023151172A1 (fr) | 2022-02-09 | 2022-04-08 | Vaccin à vecteur adénoviral pour la prévention contre une souche omicron du sars-cov-2 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114150005B (fr) |
WO (1) | WO2023151172A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114150004B (zh) * | 2022-02-09 | 2022-04-22 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2奥密克戎突变株病毒抗原肽的核酸序列及其应用 |
CN114150005B (zh) * | 2022-02-09 | 2022-04-22 | 广州恩宝生物医药科技有限公司 | 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗 |
CN117567572A (zh) * | 2022-04-01 | 2024-02-20 | 中国科学院微生物研究所 | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 |
CN115453113A (zh) * | 2022-04-13 | 2022-12-09 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 一种广谱性通用型新型冠状病毒双抗原夹心elisa抗体检测试剂盒及其应用 |
CN115716866A (zh) * | 2022-09-30 | 2023-02-28 | 珠海丽凡达生物技术有限公司 | 新型冠状病毒疫苗及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112206318A (zh) * | 2020-03-16 | 2021-01-12 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的Ad7载体疫苗 |
CN112220918A (zh) * | 2020-03-16 | 2021-01-15 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的Ad35载体疫苗 |
CN113069540A (zh) * | 2021-03-15 | 2021-07-06 | 广州恩宝生物医药科技有限公司 | 一种基于流感病毒载体的新型冠状病毒疫苗及其制备方法 |
CN113185613A (zh) * | 2021-04-13 | 2021-07-30 | 武汉大学 | 新型冠状病毒s蛋白及其亚单位疫苗 |
CN113308493A (zh) * | 2021-03-18 | 2021-08-27 | 广州恩宝生物医药科技有限公司 | 新型冠状病毒Ad26腺病毒载体疫苗及其制备方法与应用 |
CN114150005A (zh) * | 2022-02-09 | 2022-03-08 | 广州恩宝生物医药科技有限公司 | 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200643171A (en) * | 2005-06-07 | 2006-12-16 | Temasek Life Sciences Lab Ltd | Porcine circovirus type 2 vaccines |
CA2866037C (fr) * | 2007-04-23 | 2017-05-16 | Siga Technologies, Inc. | Produits chimiques, compositions et procedes de traitement et de prevention des infections a orthopoxvirus et des maladies associees |
FI3110441T3 (fi) * | 2014-02-24 | 2024-05-06 | Glaxosmithkline Biologicals S A | Uusi polysakkaridi ja sen käyttöjä |
CN106916851A (zh) * | 2017-03-01 | 2017-07-04 | 广州恩宝生物医药科技有限公司 | 一种复制缺陷型人14型腺病毒载体及其制备方法和应用 |
CN108210921A (zh) * | 2017-12-29 | 2018-06-29 | 广州恩宝生物医药科技有限公司 | 一种寨卡病毒疫苗及其制备方法 |
CN110551757A (zh) * | 2019-06-26 | 2019-12-10 | 广州恩宝生物医药科技有限公司 | 一种复制缺陷型重组人4型腺病毒及其制备方法和应用 |
CN111166875A (zh) * | 2020-01-08 | 2020-05-19 | 广州恩宝生物医药科技有限公司 | 一种腺病毒二价疫苗 |
CN110974950B (zh) * | 2020-03-05 | 2020-08-07 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 |
WO2021000969A2 (fr) * | 2020-02-23 | 2021-01-07 | 广州恩宝生物医药科技有限公司 | Séquence d'acide nucléique exprimant un peptide antigénique du virus sars-cov-2 et son utilisation |
CN110951756B (zh) * | 2020-02-23 | 2020-08-04 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
CN112300251B (zh) * | 2020-02-24 | 2022-04-05 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白及疫苗 |
CN111217917B (zh) * | 2020-02-26 | 2020-10-23 | 康希诺生物股份公司 | 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法 |
CN111218458B (zh) * | 2020-02-27 | 2020-11-20 | 珠海丽凡达生物技术有限公司 | 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法 |
MX2022011111A (es) * | 2020-03-08 | 2023-03-02 | Humanigen Inc | Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante. |
CN111218459B (zh) * | 2020-03-18 | 2020-09-11 | 中国人民解放军军事科学院军事医学研究院 | 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗 |
CN111471103A (zh) * | 2020-03-20 | 2020-07-31 | 唐山怡安生物工程有限公司 | 一种新冠病毒(2019-nCOV)的异源抗体及其制备方法 |
CN111330003A (zh) * | 2020-03-23 | 2020-06-26 | 翁炳焕 | 一种新冠肺炎反义rna多价疫苗的制备方法 |
WO2021224946A1 (fr) * | 2020-05-07 | 2021-11-11 | Bharat Biotech International Limited | Vaccin contre le coronavirus par immunisation nasale |
WO2021243219A1 (fr) * | 2020-05-29 | 2021-12-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Vaccin contre le sars-cov-2 à base d'adénovirus |
CN113750227A (zh) * | 2020-06-01 | 2021-12-07 | 康希诺生物股份公司 | 一种SARS-CoV-2疫苗 |
CN111956797B (zh) * | 2020-07-10 | 2022-05-13 | 清华大学 | 新型疫苗佐剂及其在新冠肺炎疫苗和其他疫苗中的应用 |
CN111778264B (zh) * | 2020-07-14 | 2021-06-29 | 广州佰芮慷生物科技有限公司 | 基于新型腺病毒载体Sad23L和/或Ad49L的新型冠状病毒肺炎疫苗 |
CN112618707B (zh) * | 2020-10-15 | 2023-07-04 | 广州达博生物制品有限公司 | 一种SARS-CoV-2冠状病毒疫苗及其制备方法 |
CN112386684B (zh) * | 2020-11-12 | 2023-12-05 | 广东昭泰细胞生物科技有限公司 | 一种covid-19疫苗及其制备方法和应用 |
CN112552380B (zh) * | 2020-12-10 | 2021-12-24 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原及其应用 |
CN114106166B (zh) * | 2022-01-29 | 2022-05-06 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗新冠病毒中和性抗体d2及其应用 |
-
2022
- 2022-02-09 CN CN202210120315.4A patent/CN114150005B/zh active Active
- 2022-04-08 WO PCT/CN2022/085800 patent/WO2023151172A1/fr unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112206318A (zh) * | 2020-03-16 | 2021-01-12 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的Ad7载体疫苗 |
CN112220918A (zh) * | 2020-03-16 | 2021-01-15 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的Ad35载体疫苗 |
CN113069540A (zh) * | 2021-03-15 | 2021-07-06 | 广州恩宝生物医药科技有限公司 | 一种基于流感病毒载体的新型冠状病毒疫苗及其制备方法 |
CN113308493A (zh) * | 2021-03-18 | 2021-08-27 | 广州恩宝生物医药科技有限公司 | 新型冠状病毒Ad26腺病毒载体疫苗及其制备方法与应用 |
CN113185613A (zh) * | 2021-04-13 | 2021-07-30 | 武汉大学 | 新型冠状病毒s蛋白及其亚单位疫苗 |
CN114150005A (zh) * | 2022-02-09 | 2022-03-08 | 广州恩宝生物医药科技有限公司 | 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Also Published As
Publication number | Publication date |
---|---|
CN114150005A (zh) | 2022-03-08 |
CN114150005B (zh) | 2022-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023151172A1 (fr) | Vaccin à vecteur adénoviral pour la prévention contre une souche omicron du sars-cov-2 | |
CN110974950B (zh) | 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 | |
Guo et al. | Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector‐based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus | |
WO2023151173A1 (fr) | Séquence d'acide nucléique exprimant le peptide antigénique du virus de la souche mutante du sars-cov-2 omicron, et son utilisation | |
US10760096B2 (en) | Human type 55 replication defective adenovirus vector, method for preparing same and uses thereof | |
US9750801B2 (en) | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof | |
US20210283244A1 (en) | Adenovirus-vectored vaccine for preventing sars-cov-2 infection | |
CN111778264B (zh) | 基于新型腺病毒载体Sad23L和/或Ad49L的新型冠状病毒肺炎疫苗 | |
WO2022193552A1 (fr) | Vaccin basé sur un vecteur d'adénovirus de type 26 (ad26) contre le sars-cov-2, son procédé de préparation et son application | |
Kim et al. | A single subcutaneous or intranasal immunization with adenovirus‐based SARS‐CoV‐2 vaccine induces robust humoral and cellular immune responses in mice | |
WO2021139147A1 (fr) | Vaccin à adénovirus bivalent | |
CN110616199A (zh) | 一种复制缺陷型重组人7型腺病毒及其制备方法和应用 | |
CN110551757A (zh) | 一种复制缺陷型重组人4型腺病毒及其制备方法和应用 | |
EP2855685A1 (fr) | Vecteurs adénoviraux pour la transduction de tissus vasculaires | |
WO2023024525A1 (fr) | Vaccin à vecteur adénovirus pour la prévention de la souche d'origine de sras-cov-2 et du variant bêta de sras-cov-2 | |
WO2022007774A1 (fr) | Nouveau vecteur d'adénovirus de chimpanzé, son procédé de construction et son application | |
CN115772528A (zh) | 用于预防非洲猪瘟的腺病毒载体疫苗及其应用 | |
Yamasaki et al. | Development of a method for effective amplification of human adenovirus 40 | |
KR20220012863A (ko) | 아데노바이러스 유전자 요법 벡터 생산성 및 감염성을 증가시키는 아데노바이러스 폴리펩타이드 ix | |
CN115976078B (zh) | 一种广谱的腺病毒载体新冠疫苗 | |
WO2021184987A1 (fr) | Vaccin à vecteur ad7 pour la prévention d'une infection par sras-cov-2 | |
JP2011505837A (ja) | アデノウイルス血清14型に対するワクチン | |
EA045436B1 (ru) | Аденовирусные векторы и пути их применения | |
Evans | Regulation of adenovirus infection by E4ORF3-induced reorganization of PML nuclear domains | |
WO2004108939A2 (fr) | Regions d'encapsidation d'adenovirus bovins et region de controle transcriptionnel e1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22925533 Country of ref document: EP Kind code of ref document: A1 |